Research and Development TD Metabolism, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany.
PLoS One. 2010 Mar 4;5(3):e9540. doi: 10.1371/journal.pone.0009540.
Insulin glargine (Lantus) is a long-acting basal insulin analog that demonstrates effective day-long glycemic control and a lower incidence of hypoglycemia than NPH insulin. After subcutaneous injection insulin glargine is partly converted into the two main metabolites M1 ([Gly(A21)]insulin) and M2 ([Gly(A21),des-Thr(B30)]insulin). The aim of this study was to characterize the glargine metabolites in vitro with regard to their insulin receptor (IR) and IGF-1 receptor (IGF1R) binding and signaling properties as well as their metabolic and mitogenic activities.
The affinity of human insulin, insulin glargine and its metabolites to the IR isoforms A and B or IGF1R was analyzed in a competitive binding assay using SPA technology. Receptor autophosphorylation activities were studied via In-Cell Western in CHO and MEF cells overexpressing human IR-A and IR-B or IGF1R, respectively. The metabolic response of the insulins was studied as stimulation of lipid synthesis using primary rat adipocytes. Thymidine incorporation in Saos-2 cells was used to characterize the mitogenic activity.
The binding of insulin glargine and its metabolites M1 and M2 to the IR were similar and correlated well with their corresponding autophosphorylation and metabolic activities in vitro. No differences were found towards the two IR isoforms A or B. Insulin glargine showed a higher affinity for IGF1R than insulin, resulting in a lower EC(50) value for autophosphorylation of the receptor and a more potent stimulation of thymidine incorporation in Saos-2 cells. In contrast, the metabolites M1 and M2 were significantly less active in binding to and activation of the IGF1R and their mitogenicity in Saos-2 cells was equal to human insulin. These findings strongly support the idea that insulin glargine metabolites contribute with the same potency as insulin glargine to blood glucose control but lead to significantly reduced growth-promoting activity.
胰岛素甘精(来得时)是一种长效基础胰岛素类似物,与 NPH 胰岛素相比,它能更有效地全天控制血糖,并降低低血糖的发生率。皮下注射胰岛素甘精后,部分转化为两种主要代谢物 M1([Gly(A21)]胰岛素)和 M2([Gly(A21),des-Thr(B30)]胰岛素)。本研究旨在研究甘精胰岛素及其代谢物与胰岛素受体(IR)和 IGF-1 受体(IGF1R)结合及信号转导特性,以及它们的代谢和促有丝分裂活性。
采用 SPA 技术的竞争结合测定法分析人胰岛素、胰岛素甘精及其代谢物与人胰岛素受体(IR)A 型和 B 型异构体或 IGF1R 的亲和力。通过在分别过表达人 IR-A 和 IR-B 或 IGF1R 的 CHO 和 MEF 细胞中进行 In-Cell Western 研究,研究受体自身磷酸化活性。使用原代大鼠脂肪细胞作为刺激脂质合成,研究胰岛素的代谢反应。用 Saos-2 细胞中的胸苷掺入来描述促有丝分裂活性。
胰岛素甘精及其代谢物 M1 和 M2 与 IR 的结合相似,与其在体外的相应自身磷酸化和代谢活性密切相关。在两种 IR 同工型 A 或 B 中未发现差异。胰岛素甘精与 IGF1R 的亲和力高于胰岛素,导致受体自身磷酸化的 EC50 值更低,并更有效地刺激 Saos-2 细胞中的胸苷掺入。相比之下,代谢物 M1 和 M2 与 IGF1R 的结合和激活活性明显较弱,其在 Saos-2 细胞中的促有丝分裂活性与人胰岛素相当。这些发现强烈支持这样的观点,即胰岛素甘精代谢物与胰岛素甘精一样具有控制血糖的效力,但会导致促生长活性显著降低。